Journal
CANCERS
Volume 6, Issue 4, Pages 2296-2312Publisher
MDPI
DOI: 10.3390/cancers6042296
Keywords
massively parallel sequencing; next generation sequencing; clinical oncology; validation
Categories
Funding
- Queensland Government Smart Futures Co-Investment Fund and Cancer Australia
- Life Technologies
- Agilent Technologies
Ask authors/readers for more resources
Compelling evidence supports the transition of next generation sequencing ( NGS) technology from a research environment into clinical practice. Before NGS technologies are fully adopted in the clinic, they should be thoroughly scrutinised for their potential as powerful diagnostic and prognostic tools. The importance placed on generating accurate NGS data, and consequently appropriate clinical interpretation, has stimulated much international discussion regarding the creation and implementation of strict guidelines and regulations for NGS clinical use. In the context of clinical oncology, NGS technologies are currently transitioning from a clinical research background into a setting where they will contribute significantly to individual patient cancer management. This paper explores the steps that have been taken, and those still required, for the transition of NGS into the clinical area, with particular emphasis placed on validation in the setting of clinical oncology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available